Finally, another piece of the puzzle emerges for suicide risk assessments
As the medical field has received technical innovation after technical innovation, psychiatry has been left with surprisingly litte. Now, with the EDOR-test, a new and objective method for assessing suicide risk in patients with a primary depression is available.
What is hyporeactivity and the EDOR® test?
The EDOR test is based on analysing immediate and non- conscious electrodermal reactions to sound stimuli. Reaction patterns showing fast habituation are identified as hyporeactive, functioning as a marker for high risk of suicide and violent suicide attempts in patients with a primary depression.
Hyporeactivity as a suicide risk marker is stable over time, remains in remission and in later depression episodes. It is also independent from age, gender, symptoms of depression, severity or depth of depressive state and serotonin activity (5-HIAA in liquor).
How it can be used in clinical routine
Information provided by the test functions as an objective complement to the overall clinical interview and patient history. Combining information about patients with the EDOR Test provides a more complete basis for assessing suicide risk, a risk unknown to both patient and clinician.
EDOR Test information support assessing risk, and helps with:
- Managing limited psychiatric care resources by allocating costly activities or care time to the right patients
- Decisions on treatment plans tailored to the patients’ needs and situation over time
- Patient and treatment team communication
What the test can mean for the patient
Irrespective of test result, experience from clinical use is that the information can help the patient and ensuring a feeling that patients are taken seriously at the clinic.
Patients tested as hyporeactive many times value the increased contact with the caregiver and can provide a relief from feelings of guilt. Also, it serves as an explanation to why some measures are needed. Patients with a normal reactivity can lower some of their and their relatives’ anxiety, focusing on healing from their depressive episode.
Emotra AB (“Emotra”) is presently negotiating about research collaborations on EDOR® Test with prominent university hospitals in several European countries. [...]
The Board and CEO of Emotra AB (publ) hereby present the interim report for the first six months of 2019. [...]
Emotra AB (“Emotra”) has had an eventful spring. New data which show that EDOR® can identify patients with an increased [...]
The Annual General Meeting of EMOTRA AB (publ) was held today, May 15, 2019. The resolutions, summarised below, were all [...]